The agreement resolves litigation alleging the biotech offered illegal discounts to cancer clinics. J&J’s OrthoBiotech division had filed a lawsuit charging Amgen bundled meds - Neupogen, Neulasta and Aranesp - and, by doing so, forced the clinics to buy Aranesp instead of J&J’s Procrit.

Aranesp is a longer-lasting version of Amgen’s anemia drug Epogen, which is marketed for treatment of kidney disease patients. Johnson & Johnson licensed Epogen and markets it under the Procrit brand name as a treatment for cancer patients undergoing chemotherapy. Amgen’s Neulasta and Neupogen increase production of infection-fighting white blood cells and are also used in chemo.

In a statement, Amgen insists its conduct was not unlawful and it admits to no wrongdoing. “We are pleased to have reached a settlement that puts this litigation behind us. We believe eliminating the expense and uncertainty of this suit is in the best interest of shareholders,” Kevin Sharer, Amgen’s chairman and ceo, says in the statement.